NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two indications
2023-06-02
NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two indications
Akeso Reported 2022 Annual Results
2023-03-16
Akeso Reported 2022 Annual Results
Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer
2023-03-14
Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer
China NMPA Approved 安尼可® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC
2023-01-16
China NMPA Approved 安尼可® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
2022-12-06
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China
2022-11-13
Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
2022-11-04
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
2022-10-31
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
Akeso's Ivonescimab(PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC
2022-10-21
Akeso's Ivonescimab(PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC
Akeso's Cadonilimab (PD-1/CTLA-4 Bi-specific) included in the 2022 CSCO Guidelines as the Top Recommendation for Cervical Cancer Immunotherapy
2022-10-17
Akeso's Cadonilimab (PD-1/CTLA-4 Bi-specific) included in the 2022 CSCO Guidelines as the Top Recommendation for Cervical Cancer Immunotherapy
Akeso Is Developing Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors
2022-10-17
Akeso Is Developing Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors
Akeso’s Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
2022-06-29
Akeso’s Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
开心体育app | 开云新人注册88元 | 竞技宝体育首页 | fb体育官方 | milan米兰官网入口 | mk足球 | 赢博网页 | 澳洲体彩幸运10官网（中国）幸运有限公司 | 悟空官方网站 |